PhD in Genomics: Investigating Placental Cell-Free DNA and Adverse Pregnancy Outcomes

PhD in Genomics: Investigating Placental Cell-Free DNA and Adverse Pregnancy Outcomes

Quick Decision

Strong but verify fit. This is a four-year, MRC-funded Exeter PhD built around a coherent computational chain: use pregnancy cell-free DNA (cfDNA) nucleosome footprints and placenta single-cell references to estimate gene activity, then connect those signals to genetic associations for pregnancy and perinatal outcomes. The project is a particularly close match for applicants combining biomedical or genetics knowledge with coding, statistical analysis and interest in functional genomics. Exeter names Dr Kiki Edith Cano-Gamez as lead supervisor, and her recent cfDNA work provides a clear methodological connection.

The two conditions worth resolving first are material. First, published studies already use maternal-plasma cfDNA promoter or nucleosome features to study pregnancy complications, so the proposal's distinct contribution needs to be made explicit. Second, the award welcomes international applicants but its detailed terms specify UK tuition fees; the international fee difference is not stated as covered. The official deadline is 5 January 2027; the exact closing time and time zone are not given. Review the official project specification and ask the lead supervisor about novelty, validation, named co-supervisors and confirmed dataset access before finalizing your project preference.

Research Problem and Doctoral Work

What Is Unsolved and Why It Matters

Preeclampsia, fetal growth restriction and pre-term delivery are difficult to predict before symptoms appear, and the functional consequences of many genetic variants associated with these outcomes remain uncertain. Placental development is central to pregnancy health, but repeated tissue sampling is invasive. The project proposes maternal-blood cfDNA as a less invasive source of placental information. Its working premise is that DNA fragments retain features of the chromatin and nucleosome organization of their source cells; those footprints may therefore contain clues about which genes were active.

This is a promising measurement strategy, not yet a validated real-time readout. Maternal plasma contains cfDNA from multiple sources, including maternal blood cells and placenta, and the amount and properties of placental cfDNA may change across gestation and pregnancy conditions. A recent review emphasizes that important aspects of placental cfDNA release, fragmentation and tissue contribution remain incompletely understood. The project will need to distinguish a change in placental gene activity from shifts in the mixture of DNA sources or other sequencing and cohort effects. The placental cfDNA review and foundational cfDNA nucleosome-footprint study provide useful context.

Work, Methods, and Potential Outputs

The official project description lays out four linked strands:

1. Use placenta single-cell RNA-sequencing data to identify cell-type-specific markers for key placental cell populations.
2. Apply those markers to public cfDNA sequencing data from healthy pregnancies and adverse-pregnancy-outcome cases, mapping nucleosome footprints to infer placental gene activity.
3. Lead the design and development of computational tools that predict gene activity from nucleosome footprints, extending the lead supervisor's earlier cfDNA methods.
4. Integrate cfDNA-derived gene-activity metrics with GWAS results for pregnancy and perinatal traits, using statistical-genetics approaches such as heritability partitioning and SNP enrichment.

The team also describes possible new data generation from pregnancy plasma samples held by the Genetic Beta Cell Research Bank, where useful. That addition is conditional, not a guaranteed experimental component. Advertised datasets include curated cfDNA cohorts with healthy and affected pregnancies, GWAS summary statistics for placental weight and birthweight, longitudinal expression data from the Pregnancy Outcome Prediction Study 2, and a placenta single-cell atlas. The project specification does not give cohort sizes, exact phenotypes or gestational time points, data-access status, software stack, or a required balance between computational and wet-lab work.

The expected contribution is new computational methods and functional context for disease-associated genetic variation; the project does not promise a clinically validated biomarker or causal mechanism. A useful interview question is how validation will be separated from method development: for example, whether the team has independent cohorts, consistent phenotype definitions and enough metadata to account for gestational age and source-cell mixture.

School, Programme and Field Context

The project document lists the University of Exeter as the primary institution and Clinical and Biomedical Sciences as the department. The University of Exeter's official contact page places it in Exeter, Devon, UK. The department's broader research portfolio includes genomic technology, AI and data science, biostatistics, clinical research and translational work. The department also describes clinical-trials and NIHR research infrastructure; public project materials do not say that this studentship will use a particular trial unit, clinical facility or sample collection.

The studentship belongs to the MRC Functional Genomics Doctoral Landscape Award, a four-year national programme spanning Exeter, Cambridge, Edinburgh, Imperial, King's and Oxford. Training is described as interdisciplinary and often inter-institutional, with shared training, cohort meetings, networking and collaborations. The wider initiative also advertises AI/data-science training, professional development and opportunities to engage with NHS and industry partners. These are programme-level opportunities; they do not by themselves establish a joint degree or guaranteed access to every partner. The available project PDF names Exeter as primary institution and identifies Kiki Cano-Gamez as lead, but does not list the full supervisory team.

For institutional scale, Exeter's official table reports QS World University Rankings 2027: 136th of 1,504, and Times Higher Education World University Rankings 2027: joint 157th of 2,297. These are overall university positions, not rankings in functional genomics or placental biology. In REF 2021, Exeter's Clinical Medicine unit had a research-quality profile of 45% 4-star, 48% 3-star and 7% 2-star; this is a broad unit-level assessment, not a score for this project or supervisor. A current subject ranking directly covering this project's research niche was not confirmed in the available information. Exeter's ranking table and REF results state the scope and years.

Supervisor and Lab Assessment

Supervisor Research Directions

The official specification names Kiki Edith Cano-Gamez as lead supervisor; the department's staff directory lists Dr Kiki Cano-Gamez as a Lecturer in Clinical and Biomedical Sciences at Exeter. Her recent research provides close methods adjacency, although not direct evidence of pregnancy expertise in every part of this project.

The project's resource list uses initials for the people associated with the perinatal GWAS and longitudinal-expression datasets. It gives the full name of the lead supervisor but does not expand the initials ED and RF or say whether each is a formal co-supervisor. Confirm their names, supervisory roles and expected meeting arrangements.

Recent Important Publications

• Cano-Gamez et al., 2025, Cell Genomics: In a sepsis cohort with 86 plasma samples from 46 patients and 12 controls, the authors combined cfDNA concentration, methylation, fragmentation and nucleosome footprints with cell-resolved references. They found a strong increase in cfDNA during sepsis and linked tissue-origin variation to liver dysfunction. This is the closest recent methods precedent for the proposed tool, but sepsis and placental biology are different settings. Read the study.
• Beaumont et al., 2023, Nature Genetics: This GWAS identified 40 placental-weight association signals and separated signals shared with fetal growth from those more specific to placental weight. It also reported genetic links to preeclampsia and gestational duration. This gives the project a relevant genetic substrate, while leaving molecular mechanisms for functional follow-up. Read the study.
• Hoffman et al., 2026, medRxiv preprint: The manuscript describes 3,776 RNA-seq samples from 1,083 genotyped individuals across four time points to investigate maternal immune-gene trajectories and changing genetic regulation during pregnancy. It is not peer-reviewed and describes maternal immune expression, not direct placental expression validation. Read the preprint.

Lab, Resources, and Collaboration Environment

The advertised data links are a strength: pregnancy cfDNA cohorts, perinatal GWAS, longitudinal pregnancy expression and a placenta single-cell atlas can support a more integrated analysis than a single assay alone. The Vento-Tormo group's 2018 maternal–fetal interface atlas profiled roughly 70,000 cells and provides cell-type context, though its early-pregnancy window may not match every cfDNA cohort. The atlas paper is a foundational resource rather than evidence that the group has committed project-specific access.

The lead supervisor's 2025 cfDNA publication is a strong methods connection. A key distinction to ask about is how this project extends those tools for placental source separation and gene activity, and how it builds on pregnancy-specific studies already in the literature. The official project PDF says the team has access to key datasets, but it does not list sample counts, permissions, data-release schedules or exactly which collaborations are formally committed.

Field Outlook and Career Relevance

The work builds skills in computational genomics, reproducible tool development, statistical genetics, single-cell reference analysis and interpretation of clinical/biological cohorts. These can transfer to academic functional genomics, bioinformatics, clinical genomics and life-sciences R&D roles. Skills England's 2026 assessment projects roughly 66,000 additional jobs (44%) in priority life-sciences occupations from 2025 to 2035, with most projected new employment requiring level 4 qualifications or above and growing demand for hybrid science/data/AI skills. The government also has a Life Sciences Jobs Plan addressing workforce needs. These are broad, indicative sector-level signals, not forecasts of PhD-specific jobs or placement outcomes. See the life-sciences skills assessment and Life Sciences Jobs Plan.

Funding, Application, and Living Cost

The award page states:

• Deadline: 5 January 2027. No exact closing time or time zone is stated.
• Duration: four years full-time; part-time study is also available.
• Stipend: £21,805 per year for 2026/27, matching the UK Research Council minimum and updated annually.
• Fees: the detailed funding section says UK tuition fees. The award is open to UK and international applicants.
• Research/training support: up to £5,000 per year.

The project summary also says Home tuition fees and a stipend for up to four years. This is consistent with the detailed UK-fee wording. The award page's short summary uses “full tuition fees” but does not clarify international fee status. Exeter's 2026/27 PGR fee table lists UK research fees at £5,238 and international science PGR fees in a £23,800–£29,900 range. This is an illustrative gap of about £18,562–£24,662 before confirming the project-specific fee; it is not a quote and there is no evidence that the award covers the difference. International applicants should obtain a written answer from admissions before deciding to apply. Award terms and Exeter PGR fees give the primary details.

For living costs, Exeter estimates a single student's basic local budget at £1,300–£2,000 per month, or £316–£421 per week, based on local spending in April 2026. Dividing the 2026/27 stipend by 52 gives approximately £419 per week, close to the top of that estimate. The University's 2026/27 accommodation table lists postgraduate self-catered standard-room examples from about £124.74 per week under 44- or 51-week contracts. ONS reports an average Exeter private rent of £1,318 per month in September 2026 across property types; the one-bedroom average was £914 and two-bedroom £1,130. These city averages are not student-room prices. The figures suggest lower-cost halls or shared housing may make the stipend more workable; housing availability, bills, contract length and personal circumstances will materially change the budget. Exeter's student budget, 2026/27 accommodation prices and ONS Exeter rent data support this comparison.

Applicant Fit and Preparation

Required Background and Skills

The formal threshold is a relevant 2:1 honours degree or international equivalent. The award lists genetics, molecular biology, biomedical science, human biology, biochemistry, medicine, healthcare professions, bioinformatics, computer science and statistics among relevant subjects. Selection is based on academic merit. The typical English requirement is IELTS 7.0 overall with no component below 6.5, or equivalent; evidence must be in by the deadline when required. These are programme criteria, not a project-specific coding test.

Preferred Experience and Suggested Preparation

The project description requires the student to lead computational-tool development and combine genome-scale data with statistical genetics, but it does not specify a programming language or say that prior cfDNA, single-cell or wet-lab work is mandatory. Applicants can strengthen an application by showing a reproducible coding/statistical project, experience interpreting heterogeneous biological data, and a clear account of validation choices. These are preparation suggestions, not additional official entry conditions.

The application is two-part: an Exeter online application and an FGx-DLA Applicant Questionnaire. Applicants may list up to three project preferences, but only one application per person is accepted. The portal submission includes full or interim transcripts, a maximum two-page CV, two references, and English evidence if applicable. Referees must not be members of the prospective supervisory team. If shortlisted and references were not initially uploaded, referees must email institutional letters seven days before interview. Documents must be in English; certified translations of qualifications and transcripts are required. The award page says missing documents prevent shortlisting. See the official application and eligibility instructions.

Next Actions and Questions to Verify

Before Applying

• Ask Dr Cano-Gamez how the proposed work differs from the 2025 cfDNA-footprint pregnancy study and earlier plasma-DNA promoter-profiling classifiers, and what independent validation is available.
• If you would pay international fees, ask Exeter admissions to confirm the exact fee and whether any written award or other source covers the difference above the UK rate.
• Request the full names and roles of ED and RF, the confirmed pregnancy cohorts, sample counts, phenotype definitions and gestational time points.
• Confirm the deadline time zone/closing hour, exact project start date and the application materials for your degree/English-test circumstances.

At Interview

• Which coding languages, cfDNA pipelines, single-cell tools and GWAS/statistical-genetics methods are expected on arrival, and which training is provided?
• How will the analysis distinguish placental gene activity from maternal blood-cell contributions and gestational or cohort effects?
• What is the primary validation target: gene-activity inference, functional interpretation of GWAS loci, complication prediction, or a staged combination?
• What compute resources, data permissions and project milestones are already in place?

Before Accepting an Offer

• Confirm Exeter registration and degree award, the complete supervisory team and supervision cadence.
• Obtain written confirmation of fee status, the four-year award period, annual stipend uprating and any research/bench costs.
• Clarify which cohort training, partner interactions, sample access and cross-institution visits are guaranteed versus optional.

Evidence and Sources

Project and award

• MRC FGx-DLA award terms and application details
• Official project specification PDF
• Exeter FGx-DLA project and application page
• UK Human Functional Genomics doctoral training programme
• FGx-DLA first-cohort programme announcement

School, department and supervision

• University of Exeter contact and location
• Clinical and Biomedical Sciences academic staff
• Clinical and Biomedical Sciences research themes
• Exeter university rankings by year and scope
• Exeter REF 2021 results

Placental cfDNA, genetic context and recent research

• Cano-Gamez et al., 2025: cfDNA landscape in sepsis
• Beaumont et al., 2023: placental-weight GWAS
• Hoffman et al., 2026: maternal immune-expression preprint
• Li et al., 2025: cfDNA nucleosome footprints in pregnancy and pre-eclampsia
• Yuen et al., 2024: review of placental cfDNA biology
• Snyder et al., 2016: cfDNA nucleosome footprints and tissue of origin
• Vento-Tormo et al., 2018: maternal–fetal interface single-cell atlas
• Guo et al., 2020: plasma-DNA promoter profiling for pregnancy complications

Exeter costs and career market

• Exeter postgraduate research fees 2026/27
• Exeter student budgeting estimate
• Exeter accommodation options and prices for 2026/27
• ONS Exeter housing and rents
• Skills England life-sciences workforce assessment
• UK Life Sciences Jobs Plan